Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Acquisitions & Divestments (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Change in Acquisitions & Divestments data on record, last reported at $55.0 million in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 3.97% year-over-year to $55.0 million; the TTM value through Dec 2025 reached $227.4 million, down 21.25%, while the annual FY2025 figure was $227.4 million, 21.25% down from the prior year.
  • Change in Acquisitions & Divestments reached $55.0 million in Q4 2025 per ARQT's latest filing, up from $43.3 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $147.5 million in Q1 2023 and bottomed at $36.0 million in Q3 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $74.6 million, with a median of $67.6 million recorded in 2022.
  • Peak YoY movement for Change in Acquisitions & Divestments: surged 317.0% in 2021, then crashed 52.86% in 2024.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $72.0 million in 2021, then grew by 11.68% to $80.4 million in 2022, then plummeted by 30.36% to $56.0 million in 2023, then rose by 2.28% to $57.3 million in 2024, then dropped by 3.97% to $55.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $55.0 million in Q4 2025, $43.3 million in Q3 2025, and $60.7 million in Q2 2025.